Interferon β1a therapy changes lipoprotein metabolism in patients with multiple sclerosis

Armando Sena, Rui Pedrosa, Véronique Ferret-Sena, Rita Almeida, Maria Lurdes Andrade, Maria Graça Morais, Rémy Couderc

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To assess whether interferon β1a (IFNβ1a) therapy affects plasma lipoprotein metabolism, twelve patients with relapsing-remitting multiple sclerosis (MS) were studied during a two-year follow-up period. High density lipoprotein (HDL2) cholesterol and the HDL2/HDL3 ratio were increased at year 2 and lipoprotein (a) was transitorily increased at year 1, in comparison to baseline levels. Apolipoprotein A-I was lower and apolipoprotein E higher at year 1, only in a subgroup of patients who experienced relapses and/or progressed during therapy. These findings suggest that IFNβ1a treatment is associated with changes in the lipoprotein metabolism. Alterations in this metabolism could be related to the immunomodulatory actions of the drug and the disease activity in multiple sclerosis patients.

Original languageEnglish
Pages (from-to)209-213
Number of pages5
JournalClinical Chemistry and Laboratory Medicine
Volume38
Issue number3
Publication statusPublished - Mar 2000

Fingerprint

Metabolism
Interferons
Lipoproteins
Multiple Sclerosis
HDL Cholesterol
HDL2 Lipoprotein
Relapsing-Remitting Multiple Sclerosis
Lipoprotein(a)
Apolipoprotein A-I
Apolipoproteins E
Therapeutics
Plasmas
Recurrence
Pharmaceutical Preparations

Keywords

  • Interferon β1a
  • Lipoproteins
  • Multiple sclerosis

Cite this

Sena, A., Pedrosa, R., Ferret-Sena, V., Almeida, R., Andrade, M. L., Morais, M. G., & Couderc, R. (2000). Interferon β1a therapy changes lipoprotein metabolism in patients with multiple sclerosis. Clinical Chemistry and Laboratory Medicine, 38(3), 209-213.
Sena, Armando ; Pedrosa, Rui ; Ferret-Sena, Véronique ; Almeida, Rita ; Andrade, Maria Lurdes ; Morais, Maria Graça ; Couderc, Rémy. / Interferon β1a therapy changes lipoprotein metabolism in patients with multiple sclerosis. In: Clinical Chemistry and Laboratory Medicine. 2000 ; Vol. 38, No. 3. pp. 209-213.
@article{65dfb92c68184cdeb4acfc40cbfbfa91,
title = "Interferon β1a therapy changes lipoprotein metabolism in patients with multiple sclerosis",
abstract = "To assess whether interferon β1a (IFNβ1a) therapy affects plasma lipoprotein metabolism, twelve patients with relapsing-remitting multiple sclerosis (MS) were studied during a two-year follow-up period. High density lipoprotein (HDL2) cholesterol and the HDL2/HDL3 ratio were increased at year 2 and lipoprotein (a) was transitorily increased at year 1, in comparison to baseline levels. Apolipoprotein A-I was lower and apolipoprotein E higher at year 1, only in a subgroup of patients who experienced relapses and/or progressed during therapy. These findings suggest that IFNβ1a treatment is associated with changes in the lipoprotein metabolism. Alterations in this metabolism could be related to the immunomodulatory actions of the drug and the disease activity in multiple sclerosis patients.",
keywords = "Interferon β1a, Lipoproteins, Multiple sclerosis",
author = "Armando Sena and Rui Pedrosa and V{\'e}ronique Ferret-Sena and Rita Almeida and Andrade, {Maria Lurdes} and Morais, {Maria Gra{\cc}a} and R{\'e}my Couderc",
year = "2000",
month = "3",
language = "English",
volume = "38",
pages = "209--213",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter",
number = "3",

}

Sena, A, Pedrosa, R, Ferret-Sena, V, Almeida, R, Andrade, ML, Morais, MG & Couderc, R 2000, 'Interferon β1a therapy changes lipoprotein metabolism in patients with multiple sclerosis', Clinical Chemistry and Laboratory Medicine, vol. 38, no. 3, pp. 209-213.

Interferon β1a therapy changes lipoprotein metabolism in patients with multiple sclerosis. / Sena, Armando; Pedrosa, Rui; Ferret-Sena, Véronique; Almeida, Rita; Andrade, Maria Lurdes; Morais, Maria Graça; Couderc, Rémy.

In: Clinical Chemistry and Laboratory Medicine, Vol. 38, No. 3, 03.2000, p. 209-213.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interferon β1a therapy changes lipoprotein metabolism in patients with multiple sclerosis

AU - Sena, Armando

AU - Pedrosa, Rui

AU - Ferret-Sena, Véronique

AU - Almeida, Rita

AU - Andrade, Maria Lurdes

AU - Morais, Maria Graça

AU - Couderc, Rémy

PY - 2000/3

Y1 - 2000/3

N2 - To assess whether interferon β1a (IFNβ1a) therapy affects plasma lipoprotein metabolism, twelve patients with relapsing-remitting multiple sclerosis (MS) were studied during a two-year follow-up period. High density lipoprotein (HDL2) cholesterol and the HDL2/HDL3 ratio were increased at year 2 and lipoprotein (a) was transitorily increased at year 1, in comparison to baseline levels. Apolipoprotein A-I was lower and apolipoprotein E higher at year 1, only in a subgroup of patients who experienced relapses and/or progressed during therapy. These findings suggest that IFNβ1a treatment is associated with changes in the lipoprotein metabolism. Alterations in this metabolism could be related to the immunomodulatory actions of the drug and the disease activity in multiple sclerosis patients.

AB - To assess whether interferon β1a (IFNβ1a) therapy affects plasma lipoprotein metabolism, twelve patients with relapsing-remitting multiple sclerosis (MS) were studied during a two-year follow-up period. High density lipoprotein (HDL2) cholesterol and the HDL2/HDL3 ratio were increased at year 2 and lipoprotein (a) was transitorily increased at year 1, in comparison to baseline levels. Apolipoprotein A-I was lower and apolipoprotein E higher at year 1, only in a subgroup of patients who experienced relapses and/or progressed during therapy. These findings suggest that IFNβ1a treatment is associated with changes in the lipoprotein metabolism. Alterations in this metabolism could be related to the immunomodulatory actions of the drug and the disease activity in multiple sclerosis patients.

KW - Interferon β1a

KW - Lipoproteins

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0033623897&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 209

EP - 213

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 3

ER -

Sena A, Pedrosa R, Ferret-Sena V, Almeida R, Andrade ML, Morais MG et al. Interferon β1a therapy changes lipoprotein metabolism in patients with multiple sclerosis. Clinical Chemistry and Laboratory Medicine. 2000 Mar;38(3):209-213.